ARCHIVES

ODAC Member Critical Of Amgen For Price Incentives.

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | March 21, 2008

Download PDF Visit The Full Archive

Related Articles

Guest Editorial – Interlocking Tragedies: Lance Armstrong and CPRIT

February 15, 2013

NMP22 Assay More Effective Than Conventional Lab Test

January 27, 2006

Army Accepting Letters of Intent For Research in Breast Cancer; Plans Announcement In Sept.

July 16, 1993

FDA Didn’t Punish Duke for Failing To Seek Proper Regulatory Clearance for Three Trials

January 27, 2012

Fox Chase, UCLA, U. Washington Win Neutron Contracts

October 5, 1979

In Congress; Senate Ok’s $185 Mil. Addition For Breast Cancer

October 2, 1992